Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
71,3 CHF | +2,00% | +12,28% | +40,08% |
20/03 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
20/03 | Cosmo Pharmaceuticals N.V. geeft winstverwachting voor het jaar 2024 en omzetverwachting voor 2025 | CI |
Vakgebied
Aantal werknemers: 319
Verkoop per activiteit
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25,05% |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310,51% |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3,41% |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63,17% |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17,40% |
Verkoop per regio
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45,72% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 61 | 01-01-06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-06-05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-09-11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01-01-01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10-01-22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01-01-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28-05-21 |
Founder | 69 | 01-01-97 | |
Director/Board Member | 64 | 01-01-06 | |
Director/Board Member | 69 | 01-04-12 | |
Director/Board Member | 65 | 01-03-16 | |
Chief Executive Officer | 61 | 01-01-06 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 17 543 522 | 7 842 715 ( 44,70 %) | 1 490 681 ( 8,497 %) | 44,70 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
1 283 390 | 7.32% | 96 048 381 $ | |
REDHILL BIOPHARMA LTD. 0.58% | 69 000 010 | 0.58% | 4 250 401 $ |
Bedrijfsgegevens
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Sector
Verkoop per activiteit
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,08% | 1,27 mld. | |
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+0,74% | 209 mld. | |
+2,95% | 212 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |
- Beurs
- Aandelen
- Aandeel Cosmo Pharmaceuticals N.V. - Swiss Exchange
- Onderneming Cosmo Pharmaceuticals N.V.